Emerging EGFR-Targeted Therapy in Head and Neck Cancer
The emerging data of combinatorial approaches and novel EGFR-targeting therapeutic agents offer renewed optimism for patients with advanced HNSCC who have limited treatment options. Future progress will depend on novel agents leveraging a deeper understanding of tumor biology, innovative approaches to reduce on-target off-tumor toxic effects of targeting EGFR, and improving efficacy in the growing population of patients with HPV-positive HNSCC.
Authors
- Woochan Hwang (ORCID: https://orcid.org/0000-0002-9874-7772)
- Lori J. Wirth (ORCID: https://orcid.org/0000-0002-2629-2289)
- Jong‐Chul Park (ORCID: https://orcid.org/0000-0003-0083-5991)
- Jong Seok Ahn (ORCID: https://orcid.org/0000-0003-1189-5981)
- Hyun Ae Jung
Institutions
- Harvard University (US)
- Samsung Medical Center (KR)
- Massachusetts General Hospital (US)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1001/jamaoncol.2025.3136
- Citations
- 5
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 9.24